skip to main content
Idioma:
Mostrar Somente
Refinado por: Nome da Publicação: Blood remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
Material Type:
Artigo 		Adicionar ao Meu Espaço

Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3

Gustavo Pessini Amarante-Mendes C N Kim; L Liu; Y Huang; C L Perkins; D R Green; K Bhalla

Blood v. 91, n. 5, p. 1700-1705, 1998

1998

Localização: ICB - Inst. Ciências Biomédicas    (PC-ICB BMI SEP 1998 )(Acessar)

2
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3
Material Type:
Artigo 		Adicionar ao Meu Espaço

Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3

João Gustavo Pessini Amarante-Mendes C N Kim; L Liu; Y Huang; C L Perkins; D R Green; K Bhalla

Blood v. 91, n. 5, p. 1700-1705, 1998

1998

Localização: ICB - Inst. Ciências Biomédicas    (PC-ICB BMI SEP 1998 )(Acessar)

3
Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
Material Type:
Artigo de Congresso 		Adicionar ao Meu Espaço

Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study

Tadeusz Robak Huiqiang Huang; Jie Jim; Jun Shu; Ting Liu; Olga S Samailova; Juliana Pereira; Halyna Pylypenko; Gregor Verhoef; Noppadol Siritanaratkul; Evgenii A Osmanov; Julia Alexeeva; Jiri Mayer; Xiaonan Hong; Yoshiharu Maeda; Brendan Rooney; Helgi van de Velde; Franco Cavalli; Annual Meeting and Exposition / ASH 2014 (56. San Francisco/EUA

Blood New York v. 124, n. 21, res. 4412, suppl, 2014

New York 2014

Acesso online. A biblioteca também possui exemplares impressos.

Personalize Seus Resultados

  1. Editar

Refine Search Results

Mostrar Somente

  1. Recursos Online (1)

Data de Publicação 

De até
Refinar

Novas Pesquisas Sugeridas

Ignorar minha busca e procurar por tudo

Deste Autor:

  1. KIM, C
  2. Huang, Y
  3. Perkins, C
  4. Liu, L
  5. Bhalla, K

Neste Assunto:

  1. Imunologia
  2. Linfoma (Terapia)
  3. Sobrevida
  4. Fármacos Do Sangue E Sistema Hematopoético

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.